INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 1.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $519,000 | -44.4% | 10,837 | -27.0% | 0.00% | -50.0% |
Q1 2020 | $934,000 | -53.3% | 14,837 | -8.1% | 0.00% | -33.3% |
Q4 2019 | $2,000,000 | +249.0% | 16,137 | +86.8% | 0.00% | +200.0% |
Q3 2019 | $573,000 | -24.5% | 8,637 | -9.4% | 0.00% | 0.0% |
Q2 2019 | $759,000 | -26.2% | 9,537 | +3.7% | 0.00% | -50.0% |
Q1 2019 | $1,029,000 | +136.6% | 9,200 | +130.0% | 0.00% | +100.0% |
Q4 2016 | $435,000 | -33.9% | 4,000 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $658,000 | -33.3% | 4,000 | -39.4% | 0.00% | -50.0% |
Q4 2015 | $986,000 | -11.3% | 6,600 | -1.5% | 0.00% | 0.0% |
Q3 2015 | $1,111,000 | -29.2% | 6,700 | +3.1% | 0.00% | -33.3% |
Q2 2015 | $1,569,000 | -19.4% | 6,500 | -5.8% | 0.00% | -25.0% |
Q1 2015 | $1,946,000 | +190.0% | 6,900 | +60.5% | 0.00% | +300.0% |
Q4 2014 | $671,000 | -34.1% | 4,300 | 0.0% | 0.00% | -50.0% |
Q3 2014 | $1,018,000 | -57.0% | 4,300 | -57.0% | 0.00% | -50.0% |
Q2 2014 | $2,366,000 | -42.1% | 10,000 | -19.4% | 0.00% | -42.9% |
Q1 2014 | $4,089,000 | – | 12,400 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |